
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
CMS' ruling that Aranesp and Procrit are functionally equivalent so they should get the same reimbursement is creating a stir among drug companies which feel that one product has more advantages than the other and should deserve more payment.






